Incyte Corporation news

   Watch this stock
Showing stories 11 - 20 of about 82   

Articles published

INCY 71.00 -1.03 (-1.43%)
price chart
Biotech Beat: Analysts Weigh In on Incyte Corporation (INCY) and LOXO Oncology ...
On Sunday, Incyte Corporation reported data from its fourth successful Phase 3 study of baricitinib at the American College of Rheumatology (ACR).
Latest Analysts Reports On Incyte Corporation (NASDAQ:INCY)
Recently stock market analysts have updated their consensus ratings on shares of Incyte Corporation (NASDAQ:INCY). The latest broker reports which have been released state 8 analysts have a rating of “buy”, 7 analysts “outperform”, 1 analysts “hold”, ...
Stocks Alert: Incyte Corporation (INCY), Alnylam Pharmaceuticals, Inc. (ALNY)  News Oracle
Hot Biotech Stocks To Watch Right Now - Incyte Corporation (INCY), Opko ...  iStreetWire
Earnings Estimate Of Incyte Corporation (NASDAQ:INCY)
Brokerage firms covering Incyte Corporation (NASDAQ:INCY) have predicted its profits, revenues and price target. The stock is predicted to move to 116.77 in imminent months.
Promising stocks in today's market: Incyte Corporation (NASDAQ:INCY)
Based on the aggregate value of the company over its current share price and the total amount of outstanding stocks, the market cap of Incyte Corporation is presently reeling at 12822.84. Acting as the blue chip in today's trade, Incyte Corporation's ...
Stock Update (NASDAQ:INCY): Incyte Corporation and Eli Lilly Announce Success ...
Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with ...
Eli Lilly, Incyte Announce Baricitinib Superior To Methotrexate In ...  Tech Times
Eli Lilly & Co. (LLY), Incyte (INCY) Announce Baricitinib Phase 3 Met ...  StreetInsider.com
Why Incyte Corporation (INCY) Isnt Done Growing Earnings Yet
One such company that might be well-positioned for future earnings growth is Incyte Corporation (INCY - Analyst Report). This firm, which is in the Medical - Biomed/Gene industry, saw EPS growth of 34.1% last year, and is looking great for this year too.
Premarket Biotech Digest: Incyte Fairly Valued, Zafgen Bounces Back, Mylan ...  Seeking Alpha
Eric Siegel, Incyte Corporation (NASDAQ:INCY)'s insider Sold 2222 Shares  OctaFinance.com
Analysts Pick Incyte Corporation (NASDAQ:INCY) As Growth Firm
Incyte Corporation (NASDAQ:INCY) has successfully scored a place in the group of firms assigned with top Growth Style score.
Incyte Corporation (NASDAQ:INCY): Quarterly Earnings Update
As per the research firms that were included in Zacks Research survey, Incyte Corporation (NASDAQ:INCY) is projected an EPS of $0.11 for last quarter.
Stock Update (NASDAQ:INCY): Incyte Corporation's Jakafi to be Featured in over ...
Incyte Corporation (NASDAQ:INCY) announces that more than 60 abstracts featuring data from its ongoing clinical development program for Jakafi� (ruxolitinib) will be presented at the upcomingAmerican Society of Hematology (ASH) 57th Annual Meeting ...
Incyte's Jakafi� (ruxolitinib) to be Featured in over 60 Abstracts at ...  Business Wire (press release)
Incyte Corporation (NASDAQ:INCY) Short Interest Update
Incyte Corporation (NASDAQ:INCY) reported a rise of 7.3% or 298,208 shares in its short interest. The short figure came in at 2.4% of the total floats.